What is the 13F Pro Quality Score for CRNX?

13F Pro ranks Crinetics Pharmaceuticals, Inc. (CRNX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CRNX's current score at https://13fpro.ai/company/CRNX (free sign-up required for the full ranking).

Which hedge funds own the most CRNX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CRNX include FMR, BlackRock,, FARALLON CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CRNX as soon as new 13F filings post.

Where does 13F Pro source CRNX data?

All Crinetics Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Crinetics Pharmaceuticals, Inc. files with the SEC under CIK 1658247. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CRNX in?

Crinetics Pharmaceuticals, Inc. (CRNX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CRNX research updated on 13F Pro?

CRNX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Crinetics Pharmaceuticals, Inc.(CRNX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1658247 CRNX stock profile & AI dashboard →

13F Pro Quality Score

25.5/100

Rank #2,659 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

99.3/100

Profitability

2.2/100

Balance Sheet

5.5/100

Earnings Quality

17.5/100

Free Cash Flow

1.7/100

Institutional Flow

28.3/100

Revenue Scale

7.6/100

Dilution Risk

0.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CRNX Scores 26/100

exact factor attribution · 2026-09-11

CRNX's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.9 pts

99th pct

Institutional flow

-1.1 pts

28th pct

Earnings growth

-2.3 pts

4th pct

Shareholder dilution

-2.5 pts

0th pct

Earnings quality

-3.3 pts

18th pct

Capital efficiency

-4.5 pts

6th pct

Scale

-6.4 pts

8th pct

Profitability

-7.2 pts

2th pct

Free cash flow

-7.2 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CRNX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Crinetics Pharmaceuticals, Inc. (CRNX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRNX at 25.5/100 on a 32-signal composite quality model, placing it at rank #2,659 of 2,961 stocks — the bottom half of the AI-ranked universe. CRNX scores in the top quartile across revenue growth (99.3). Areas of concern include free cash flow (1.7) and profitability (2.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Crinetics Pharmaceuticals, Inc. reports quarterly revenue of $25.1M, net income of $-120.9M, free cash flow of $-94.7M. Top institutional holders of CRNX by reported 13-F value include FMR, BlackRock, FARALLON CAPITAL MANAGEMENT, based on the most recent SEC filings. CRNX trades on the Nasdaq exchange and files with the SEC under CIK 1658247. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Crinetics Pharmaceuticals, Inc. directly from SEC EDGAR. Crinetics Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 6 and 29 since 2021, currently 25.5 — an improving long-term trajectory across 63 quarterly and live scoring snapshots.

✦

Fun facts about Crinetics Pharmaceuticals, Inc.

Quirks, history, and lore behind CRNX — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in San Diego, California · focused on endocrine and rare diseases.
2
The Numbers
Still pre-revenue in the traditional sense, it burns cash to fund a pipeline of several candidates — a small-cap biotech with a market cap in the low billions.
3
The History
Founded in the 2010s, it was built around a singular scientific bet: that non-peptide, oral small molecules could do what injectable hormone analogues have done for decades, but better.
4
The Secret
Its entire pipeline targets the somatostatin receptor system — a niche so specific most pharma giants ignored it, which is exactly where this company planted its flag.
5
The Lore
Its lead program targets acromegaly — a rare condition caused by excess growth hormone — aiming to replace monthly injections with a daily pill.
6
The Giveaway
Ticker CRNX, a San Diego biotech whose drug paltusotine could make acromegaly patients trade the needle for a once-daily oral therapy.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$25.1M

Net Income

Q2 2026

$-120.9M

Free Cash Flow

Q2 2026

$-94.7M

ROIC

Q2 2026

-44.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+640.7% YoY

$7.7MFY 2025

FY22 $4.7MFY23 $4.0MFY24 $1.0MFY25 $7.7M

Net Income

-55.9% YoY

$-465.3MFY 2025

FY22 $-163.9MFY23 $-214.5MFY24 $-298.4MFY25 $-465.3M

Operating Income

-52.5% YoY

$-516.8MFY 2025

FY22 $-167.9MFY23 $-222.6MFY24 $-338.9MFY25 $-516.8M

EPS (Diluted)

-34.1% YoY

$-4.95FY 2025

FY22 $-3.15FY23 $-3.69FY24 $-3.69FY25 $-4.95

Total Assets

-21.5% YoY

$1.13BFY 2025

FY22 $352.2MFY23 $635.4MFY24 $1.43BFY25 $1.13B

Op. Cash Flow

-64.2% YoY

$-377.9MFY 2025

FY22 $-115.2MFY23 $-168.6MFY24 $-230.2MFY25 $-377.9M

Free Cash Flow

-63.9% YoY

$-383.7MFY 2025

FY22 $-116.9MFY23 $-173.3MFY24 $-234.0MFY25 $-383.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$7.7M +640.7%	$1.0M -74.1%	$4.0M -15.3%	$4.7M +339.4%	$1.1M +1418.3%	$71.0K
Net Income	$-465.3M -55.9%	$-298.4M -39.1%	$-214.5M -30.9%	$-163.9M -52.3%	$-107.6M -45.8%	$-73.8M
Operating Income	$-516.8M -52.5%	$-338.9M -52.2%	$-222.6M -32.6%	$-167.9M -55.9%	$-107.7M -43.7%	$-75.0M
EPS (Diluted)	$-4.95 -34.1%	$-3.69 +0.0%	$-3.69 -17.1%	$-3.15 -12.5%	$-2.80 -15.7%	$-2.42
Total Assets	$1.13B -21.5%	$1.43B +125.8%	$635.4M +80.4%	$352.2M +0.3%	$351.0M +91.3%	$183.4M
Operating Cash Flow	$-377.9M -64.2%	$-230.2M -36.5%	$-168.6M -46.3%	$-115.2M -30.0%	$-88.6M -42.8%	$-62.0M
Free Cash Flow	$-383.7M -63.9%	$-234.0M -35.1%	$-173.3M -48.3%	$-116.9M -31.3%	$-89.0M -43.1%	$-62.2M

Get alerted when CRNX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Crinetics Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CRNX

FMR LLC
$592.7M15,840,219 sh
BlackRock, Inc.
$365.2M9,758,938 sh
FARALLON CAPITAL MANAGEMENT LLC
$336.4M8,989,098 sh
WELLINGTON MANAGEMENT GROUP LLP
$266.8M7,131,084 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$241.9M6,463,551 sh
PRICE T ROWE ASSOCIATES INC /MD/
$232.5M6,212,681 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$180.8M4,832,614 sh
VANGUARD CAPITAL MANAGEMENT LLC
$177.6M4,745,262 sh
Jupiter Topco LLC
$170.5M4,557,689 sh
GEODE CAPITAL MANAGEMENT, LLC
$102.1M2,727,633 sh

Fund	Value	Shares
FMR LLC	$592.7M	15,840,219
BlackRock, Inc.	$365.2M	9,758,938
FARALLON CAPITAL MANAGEMENT LLC	$336.4M	8,989,098
WELLINGTON MANAGEMENT GROUP LLP	$266.8M	7,131,084
DRIEHAUS CAPITAL MANAGEMENT LLC	$241.9M	6,463,551
PRICE T ROWE ASSOCIATES INC /MD/	$232.5M	6,212,681
VANGUARD PORTFOLIO MANAGEMENT LLC	$180.8M	4,832,614
VANGUARD CAPITAL MANAGEMENT LLC	$177.6M	4,745,262
Jupiter Topco LLC	$170.5M	4,557,689
GEODE CAPITAL MANAGEMENT, LLC	$102.1M	2,727,633

Companies Similar to CRNX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

AGIO

AGIOS PHARMACEUTICALS, INC.

AI score

Very similar · 13 shared holders

FARALLON CAPITAL MANAGEMENT LLC ADAR1 Capital Management, LLC KENNEDY CAPITAL MANAGEMENT LLC

CYTK

CYTOKINETICS INC

AI score

Very similar · 18 shared holders

Polar Capital Holdings Plc T. Rowe Price Investment Management, Inc.Siren, L.L.C.

KYMR

Kymera Therapeutics, Inc.

AI score

Very similar · 20 shared holders

DRIEHAUS CAPITAL MANAGEMENT LLC BAKER BROS. ADVISORS LP T. Rowe Price Investment Management, Inc.

VRDN

Viridian Therapeutics, Inc.\DE

AI score

Similar quality profile · 11 shared holders

Bellevue Group AG BAKER BROS. ADVISORS LP Novo Holdings A/S

RYTM

RHYTHM PHARMACEUTICALS, INC.

AI score

Similar quality profile · 20 shared holders

BAKER BROS. ADVISORS LP Polar Capital Holdings Plc Siren, L.L.C.

KURA

Kura Oncology, Inc.

AI score

Similar quality profile · 10 shared holders

SUVRETTA CAPITAL MANAGEMENT, LLC Prosight Management, LP SECTOR GAMMA AS

CGON

CG Oncology, Inc.

AI score

Similar quality profile · 13 shared holders

T. Rowe Price Investment Management, Inc.ORBIMED ADVISORS LLC Bellevue Group AG

SNDX

Syndax Pharmaceuticals Inc

AI score

Similar quality profile · 12 shared holders

Hood River Capital Management LLC ORBIMED ADVISORS LLC Candriam S.C.A.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CRNX on your watchlist

Track score changes the day Crinetics Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CRNX a good stock to buy?

13F Pro's AI-powered analysis of Crinetics Pharmaceuticals, Inc. (CRNX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CRNX are available on the CRNX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CRNX is classified as a mid company.

Which hedge funds own CRNX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CRNX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Crinetics Pharmaceuticals, Inc.'s investment landscape.